

Oncology Agents
Danyelza (naxitamab-gqgk)
Effective 06/01/2025

Plan	<input checked="" type="checkbox"/> MassHealth UPPL <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
Contact Information	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
Exceptions	N/A		

Overview

Neuroblastoma is a cancer in which malignant cells form in the neuroblasts in the adrenal glands, neck, chest, or spinal cord.

Danyelza is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.

Coverage Guidelines

Authorization may be reviewed on a case by case basis for members who are new to the plan currently receiving treatment with requested medication excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted for members when all the following criteria are met:

1. Diagnosis of high-risk neuroblastoma of bone or bone marrow
2. Prescriber is an oncologist
3. Appropriate dosing
4. The member is ≥ 1 year of age
5. The member's tumor is high risk
6. The member had demonstrated a partial response, minor response, or stable disease to prior treatment (e.g., vincristine, cyclophosphamide, topotecan, doxorubicin, cisplatin, and etoposide)
7. The requested medication will be used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) agent

Continuation of Therapy

Reauthorization by physician will infer a positive response to therapy.

Limitations

1. Initial approvals and reauthorizations will be for 6 months.

References

1. Danyelza® (naxitamab-gqgk) [prescribing information]. New York (NY): Y-mAbs Therapeutics, Inc.; 2024 Mar.
2. FDA Approves Y-mAbs' DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma [press release on the internet]. Pipeline Review; 2020 Nov 26 [cited 2021 Feb 21]. Available from: <https://pipelinereview.com/index.php/2020112676664/Antibodies/FDA-Approves-Y-mAbs-DANYELZA-naxitamab-gqgk-for-the-Treatment-of-Neuroblastoma.html>.
3. Key Statistics About Neuroblastoma [webpage on the internet]. American Cancer Society; 2020 Jan 8 [cited 2021 Feb 21]. Available from: <https://www.cancer.org/cancer/neuroblastoma/about/key-statistics.html>.
4. Unituxin® (dinutixumab) [prescribing information]. Research Triangle Park (NC): United Therapeutics Corp; 2020 Sept.
5. Shohet JM, Lowas SR, Nuchtern JG. Treatment and prognosis of neuroblastoma. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2021 Nov [cited 2021 Dec 20]. Available from: <https://www.uptodate.com/contents/treatment-and-prognosis-of-neuroblastoma>.

Review History

09/21/2022 – Reviewed and Created for Sept P&T; matched MH UPPL. Effective 1/1/23

05/15/2025 – Reviewed and updated for P&T. Updated formatting and references. Danyelza will be managed through the medical benefit only. Effective 6/1/25

